PURPOSE: Enzastaurin is a potent, serine-threonine kinase inhibitor which selectively targets PKCβ and PI3K/AKT signaling pathways to reduce cell proliferation, induce apoptosis, and inhibit angiogenesis. As PKCbeta and PI3K/AKT signaling are both involved in breast cancer pathogenesis, this phase II study evaluated the efficacy and toxicity of enzastaurin in previously treated patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Eligible patients had histologically confirmed MBC with measurable disease, and must have received prior anthracycline and taxane chemotherapy, but not more than two prior regimens for MBC. Human epidermal growth factor 2 (HER2)-positive patients must have progressed on prior trastuzumab therapy. Enzastaurin, 1,125-mg loading dose on day 1 followed by 500 mg daily, was administered orally in 28-day cycles. Response was assessed every 2 cycles according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RESULTS: Twenty-one patients enrolled between November 2006 and September 2007. Fourteen (66.7%) patients completed at least two cycles of therapy. No patients developed Grade 3/4 hematologic toxicity. Grade 3 nonhematologic toxicity was rare (<5%) and most commonly attributed to MBC progression. There were no objective responses and no patients with stable disease for >/=6 months. Median progression-free survival was 1.68 months (95%CI: 1.02, 1.74). CONCLUSIONS: Enzastaurin monotherapy was well tolerated, but demonstrated no activity in patients with heavily pretreated MBC.
PURPOSE:Enzastaurin is a potent, serine-threonine kinase inhibitor which selectively targets PKCβ and PI3K/AKT signaling pathways to reduce cell proliferation, induce apoptosis, and inhibit angiogenesis. As PKCbeta and PI3K/AKT signaling are both involved in breast cancer pathogenesis, this phase II study evaluated the efficacy and toxicity of enzastaurin in previously treated patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Eligible patients had histologically confirmed MBC with measurable disease, and must have received prior anthracycline and taxane chemotherapy, but not more than two prior regimens for MBC. Human epidermal growth factor 2 (HER2)-positive patients must have progressed on prior trastuzumab therapy. Enzastaurin, 1,125-mg loading dose on day 1 followed by 500 mg daily, was administered orally in 28-day cycles. Response was assessed every 2 cycles according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RESULTS: Twenty-one patients enrolled between November 2006 and September 2007. Fourteen (66.7%) patients completed at least two cycles of therapy. No patients developed Grade 3/4 hematologic toxicity. Grade 3 nonhematologic toxicity was rare (<5%) and most commonly attributed to MBC progression. There were no objective responses and no patients with stable disease for >/=6 months. Median progression-free survival was 1.68 months (95%CI: 1.02, 1.74). CONCLUSIONS:Enzastaurin monotherapy was well tolerated, but demonstrated no activity in patients with heavily pretreated MBC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jeany M Rademaker-Lakhai; Laurens V Beerepoot; Niven Mehra; Sandra A Radema; Rianne van Maanen; Joost S Vermaat; Els O Witteveen; Carla M Visseren-Grul; Luna Musib; Nathan Enas; Gertjan van Hal; Jos H Beijnen; Jan H M Schellens; Emile E Voest Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Michael J Robertson; Brad S Kahl; Julie M Vose; Sven de Vos; Mary Laughlin; Patrick J Flynn; Kendrith Rowland; Jose C Cruz; Stuart L Goldberg; Luna Musib; Christelle Darstein; Nathan Enas; Jeffery L Kutok; Jon C Aster; Donna Neuberg; Kerry J Savage; Ann LaCasce; Donald Thornton; Christopher A Slapak; Margaret A Shipp Journal: J Clin Oncol Date: 2007-03-26 Impact factor: 44.544
Authors: Kristan A Keyes; Larry Mann; Michael Sherman; Elizabeth Galbreath; Linda Schirtzinger; Darryl Ballard; Yun-Fei Chen; Philip Iversen; Beverly A Teicher Journal: Cancer Chemother Pharmacol Date: 2003-10-31 Impact factor: 3.333
Authors: Jeremy R Graff; Ann M McNulty; Kimberly Ross Hanna; Bruce W Konicek; Rebecca L Lynch; Spring N Bailey; Crystal Banks; Andrew Capen; Robin Goode; Jason E Lewis; Lillian Sams; Karen L Huss; Robert M Campbell; Philip W Iversen; Blake Lee Neubauer; Thomas J Brown; Luna Musib; Sandaruwan Geeganage; Donald Thornton Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Melody A Cobleigh; Virginia K Langmuir; George W Sledge; Kathy D Miller; Latrice Haney; William F Novotny; James D Reimann; Amy Vassel Journal: Semin Oncol Date: 2003-10 Impact factor: 4.929
Authors: Lindsay B Kilburn; Mehmet Kocak; Rodney L Decker; Cynthia Wetmore; Murali Chintagumpala; Jack Su; Stewart Goldman; Anuradha Banerjee; Richard Gilbertson; Maryam Fouladi; Larry Kun; James M Boyett; Susan M Blaney Journal: Neuro Oncol Date: 2014-11-27 Impact factor: 12.300
Authors: Julie A Wallace; Jason R Pitarresi; Nandini Sharma; Marilly Palettas; Maria C Cuitiño; Steven T Sizemore; Lianbo Yu; Allen Sanderlin; Thomas J Rosol; Kamal D Mehta; Gina M Sizemore; Michael C Ostrowski Journal: Front Oncol Date: 2014-04-23 Impact factor: 6.244
Authors: T Shimokawa; M Seike; C Soeno; H Uesaka; A Miyanaga; H Mizutani; K Kitamura; Y Minegishi; R Noro; T Okano; A Yoshimura; A Gemma Journal: Br J Cancer Date: 2012-02-14 Impact factor: 7.640